CD4 and cancer: Cross-presentation and cross-priming are generally thought to be carried out preferentially by cDC1, whereas cDC2 are known as APCs serving CD4 T lymphocytes both in the setting of infection and cancer (Binnewies et al., 2019; Durai and Murphy, 2016).